Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimagrumab in Sporadic Inclusion Body Myositis
NCT01423110Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2011
- Primary completion
- May 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bimagrumab in sporadic inclusion body myositis (sIBM), sponsored by Novartis. Started Aug 2011; status: completed.
02
Drugs
bimagrumab
03
Conditions
sporadic inclusion body myositis (sIBM)
Beyond the preview
Go deeper on NCT01423110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01423110.